In marked contrast, in both MCF-7 and MDA-MB-231 breast cancer cells in which CPT1A was knocked down, PRL increased enzyme activity by 10 and 17%, respectively (Figure 6B and 6C), although levels were not restored to baseline (reflected by treatment with vehicle only). This evidence concerns the gene PRL and breast carcinoma.